Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, ...

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Considering dual biologic therapy for psoriasis or eczema? Get a firsthand account of navigating insurance, potential side effects, and treatment outcomes.

The atopic dermatitis therapeutics market is poised for steady growth, with revenues projected to rise from USD 15.43 billion in 2024 to USD 29.5 billion by 2033. This reflects a compound annual ...

President Trump signed an executive order aiming to cut prescription drug costs by bringing the price the U.S. pays in line with comparable developed nations.

Key takeaways: Dupilumab and mepolizumab are the only FDA-approved biologics for adults with COPD and an eosinophilic phenotype.

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new study finds.

Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

People in states that have banned abortion were more than twice as likely to receive them later in pregnancy, according to a new study by researchers at UC San Francisco. The delays are primarily due ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Its primary purpose is treatment, ensuring a robust evaluation of Dupilumab’s efficacy and safety. The study began on January 3, 2024, with primary completion expected in 2025.